WHEAT RIDGE, CO, Jun 13, 2007 (MARKET WIRE via COMTEX) -- GeneThera, Inc. (GTHA) announced today that it has entered into substantial negotiations with Mezey Howarth Racing Stables to develop a molecular test and vaccine for Equine infectious anemia virus (EIAV). Equine infectious anemia (EIA) is an infectious and potentially fatal horse viral disease. Currently, there is no treatment for EIAV. In 2004, there were 330 confirmed cases of EIAV.
"The importance of accurate testing is essential considering that once a horse is infected with EIAV, the virus quickly can spread the entire stable," said Dr. Tony Milici of GeneThera. "Because this disease is so highly contagious, it is very important we identify any horse with EIAV," said Paul Howarth of Mezey Howarth Racing Stables, "but we would like to be able to develop a treatment for the disease instead of losing a revenue-producing asset."
The negotiations, which are ongoing, are expected to be completed soon. It is anticipated that testing will begin in October 2007.
